PASW Nasdaq Apparel & Other Finishd Prods Of Fabrics & Similar Matl Financials FY2023βFY2025
Ping An Biomedical Co., Ltd. had $4.7M of revenue in fiscal 2025, down 61.1% on the year before.
Hi! I read Ping An Biomedical Co., Ltd.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β61.1%
No. Sales fell 61.1% last year.
Does it make a profit?
β37.6%
No. It lost money last year.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Ping An Biomedical Co., Ltd. did it, and the next one. Share prices often move a lot on those days.
Next results
January 29, 2027
Friday Β· in 95 days
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week β| Date | Results for | Time | Source |
|---|---|---|---|
| Jan 30, 2026 | Period ended Sep 30, 2025 | During market hours | 20-F β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Ping An Biomedical Co., Ltd. had $4.7M of revenue in fiscal 2025, down 61.1% on the year before. Its operating margin was β43.1%, down 43.0Β pts: of every 100 in sales, about β43 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Margins, % of revenue
KIRA Β· Ping An Biomedical Co., Ltd. lost $1.8M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Ping An Biomedical Co., Ltd. owes $1.2M more than it holds in cash.
Cash, debt and the ratios that show how comfortably Ping An Biomedical Co., Ltd. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $0.1M | $0.0M | $0.2M |
| Debt incl. finance leases | β | $1.4M | $1.4M |
| Net debt / EBITDA | β | 1,279.4x | β |
| Debt / equity | β | β | 0.2x |
| Interest coverage | 0.4x | β0.0x | β47.8x |
| Current ratio | β | 0.8x | 2.8x |
| Quick ratio | β | 0.8x | 2.7x |
| Total assets | β | $8.1M | $9.6M |
| Total liabilities | β | $9.1M | $3.3M |
| Shareholders' equity | β$0.8M | β$1.0M | $6.4M |
| Net debt (β = net cash) | β | $1.4M | $1.2M |
KIRA Β· Its return on capital was β21.2%: every 100 invested in the business earned about β21 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Ping An Biomedical Co., Ltd. passes 3 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | β / 3 | β / 5 | 3 / 9 |
| Accruals ratio | β | β27.2% | β10.0% |
| Altman Z'' | β | β1.77 | 3.52 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | $11.7M | $12.2M | $4.7M |
| Gross profit | $0.6M | $0.8M | $0.1M |
| Operating income | $0.1M | β$0.0M | β$2.0M |
| Interest expense | $0.2M | $0.1M | $0.0M |
| Pretax income | $0.0M | β$0.1M | β$2.0M |
| Income tax | β$0.1M | β$0.1M | $0.3M |
| Net income | β$0.1M | β$0.2M | β$1.8M |
| Diluted EPS | β$0.01 | β$0.01 | β$0.10 |
| Diluted shares | 0.02B | 0.02B | 0.02B |
| Cash flow | |||
| Cash from operations | β$0.9M | $2.0M | β$0.9M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M |
| Dividends paid | $1.4M | $0.0M | β |
| Dividends and buybacks | $1.4M | $0.0M | β |
| Balance sheet | |||
| Cash and short-term investments | $0.1M | $0.0M | $0.2M |
| Total debt | β | $1.4M | $1.4M |
| Current assets | β | $7.6M | $8.9M |
| Current liabilities | β | $9.1M | $3.2M |
| Inventory | β | $0.0M | $0.1M |
| Property and equipment, net | β | $0.0M | β |
| Total assets | β | $8.1M | $9.6M |
| Total liabilities | β | $9.1M | $3.3M |
| Shareholders' equity | β$0.8M | β$1.0M | $6.4M |
| Margins | |||
| Gross margin | 5.1% | 6.2% | 2.8% |
| Operating margin | 0.7% | β0.0% | β43.1% |
| EBITDA margin | 0.8% | 0.0% | β43.0% |
| Net margin | β1.2% | β1.5% | β37.6% |
| Returns | |||
| Return on capital | β | β0.1% | β21.2% |
| Return on capital employed | β | 0.0% | β32.0% |
| Return on equity | β | β | β66.7% |
| Return on assets | β | β2.2% | β20.1% |
| Return on tangible equity | β | β | β28.0% |
| Growth | |||
| Revenue growth | β | 3.9% | β61.1% |
| Share count change | β | 0.0% | 2.7% |
| Financial health | |||
| Net debt / EBITDA | β | 1,279.4x | β |
| Debt / equity | β | β | 0.2x |
| Interest coverage | 0.4x | β0.0x | β47.8x |
| Current ratio | β | 0.8x | 2.8x |
| Quick ratio | β | 0.8x | 2.7x |
| Quality scores | |||
| Piotroski F-score | β | β | 3.0 |
| Altman Z'' | β | β1.8 | 3.5 |
| Accruals ratio | β | β27.2% | β10.0% |
Source: SEC EDGAR XBRL filings (CIK 0001897532). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in CNY under US GAAP and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only β not investment advice. Check the original filings before relying on any figure.
